dofequidar has been researched along with cyclosporine in 5 studies
| Studies (dofequidar) | Trials (dofequidar) | Recent Studies (post-2010) (dofequidar) | Studies (cyclosporine) | Trials (cyclosporine) | Recent Studies (post-2010) (cyclosporine) |
|---|---|---|---|---|---|
| 40 | 2 | 5 | 30,547 | 3,802 | 6,558 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsuruo, T | 1 |
| Ford, PJ; Germann, UA; Harding, MW; Mason, VS; Shlyakhter, D | 1 |
| Hanibuchi, M; Parajuli, P; Shrivastava, P; Sone, S; Tsuruo, T; Yano, S | 1 |
| Aoki, J; Kimura, Y; Kohno, M; Nakanishi, O; Ooka, H; Tsuruo, T | 1 |
| Hu, Y; Mizoi, K; Naitoh, Y; Sasajima, T; Satoh, T; Shimada, N; Takahashi, M | 1 |
1 review(s) available for dofequidar and cyclosporine
| Article | Year |
|---|---|
[Development of drugs to overcome drug resistance--basic approaches].
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Drug Resistance, Multiple; Humans; Leukemia P388; Leukemia, Myeloid; Mice; Mice, Nude; Quinolines; Tumor Cells, Cultured; Verapamil | 1995 |
4 other study(ies) available for dofequidar and cyclosporine
| Article | Year |
|---|---|
Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP.
Topics: Acridines; Affinity Labels; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Cyclosporine; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Etoposide; Fluoresceins; HL-60 Cells; Humans; Isoquinolines; Multidrug Resistance-Associated Proteins; Piperidines; Pyridines; Quinolines; Tetrahydroisoquinolines; Tritium; Verapamil; Vincristine | 1997 |
Circumvention of multidrug resistance by a quinoline derivative, MS-209, in multidrug-resistant human small-cell lung cancer cells and its synergistic interaction with cyclosporin A or verapamil.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Cyclosporine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Humans; Lung Neoplasms; Quinolines; Tumor Cells, Cultured; Verapamil | 1998 |
P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Caco-2 Cells; Cyclosporine; Cyclosporins; Humans; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Paclitaxel; Quinolines; Rats; Rats, Sprague-Dawley | 2002 |
(99m)Tc-MIBI imaging for prediction of therapeutic effects of second-generation MDR1 inhibitors in malignant brain tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autoradiography; Brain Neoplasms; Carcinoma 256, Walker; Cell Line, Tumor; Cell Proliferation; Cyclosporine; Cyclosporins; Cytotoxins; Drug Resistance, Neoplasm; Drug Synergism; Predictive Value of Tests; Quinolines; Radiopharmaceuticals; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon; Vincristine | 2007 |